By Nqobile Dludla
South Africa’s Aspen Pharmacare has started registering GLP-1 drugs used to treat diabetes and obesity in markets where patents are expiring soon, for approval to start manufacturing and selling likely in 2026, the CEO said on Tuesday.
Drugmakers across the globe are looking to grab a slice of the weight-loss drugs market, which is estimated to reach at least $100 billion by the end of the decade.
Aspen, which also has a presence in Asia, the Middle East, Africa, Australasia and Europe, wants a slice of the 1 billion patient pool covering type 2 diabetes and obesity as patents for these drugs expire as early as 2026 in emerging markets, Aspen CEO Stephen Saad told investors.
But the current market is characterised by treatments that are expensive and by global capacity shortages.
“To have supply in an environment which has a big market but is already strained,
You’ve reached your free article limit
Subscribe to enjoy unlimited access to trusted journalism. Cancel anytime.
Subscribe nowNeed help? molokom@insidepolitic.co.za
